{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:48:22Z","timestamp":1785840502559,"version":"3.56.0"},"reference-count":27,"publisher":"Baskent University","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.2026.0045","type":"journal-issue","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:58:43Z","timestamp":1785830323000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Gillis B, Villanueva D, Marsh W, et al. Outcomes of kidneys transplanted from hepatitis c viremic donors to naive recipients from an Appalachian rural kidney transplant program. Exp Clin Transpl. 2024;22(3):185-188. doi:10.6002\/ect.2024.0034","DOI":"10.6002\/ect.2024.0034"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Czarnecka P, Czarnecka K, Tronina O, Baczkowska T, Durlik M. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? Ren Fail. 2022;44(1):434-449. doi:10.1080\/0886022X.2022.2047069","DOI":"10.1080\/0886022X.2022.2047069"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Concepcion BP, Binari LA, Schaefer H, et al. Kidney transplantation from hepatitis C viremic deceased donors to aviremic recipients in a real-world setting. Transplant Direct. 2021;7(10):e761. doi:10.1097\/TXD.0000000000001217","DOI":"10.1097\/TXD.0000000000001217"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Reddy YNV, Reddy KP, Sise ME. HCV-infected deceased donor kidney transplantation-time to take up the offer. Am J Kidney Dis. 2020;75(6):827-829. doi:10.1053\/j.ajkd.2020.01.010","DOI":"10.1053\/j.ajkd.2020.01.010"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Rawashdeh B, Hulse J, Agarwal A. Transplant of a kidney from a hepatitis C viremic donor to a na\u00efve recipient without viral transmission: a case report. Am J Case Rep. 2021;22:e927532. doi:10.12659\/AJCR.927532","DOI":"10.12659\/AJCR.927532"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Cohen-Bucay A, Francis JM, Gordon CE. Timing of hepatitis C virus infection treatment in kidney transplant candidates. Hemodial Int. 2018;22(Suppl 1):S61-S70. doi:10.1111\/hdi.12643","DOI":"10.1111\/hdi.12643"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Chen R, Li D, Zhang M, Yuan X. Sofosbuvir\/velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors. Ann Transplant. 2021;26: e933313. doi:10.12659\/AOT.933313","DOI":"10.12659\/AOT.933313"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Gupta G, Yakubu I, Zhang Y, et al. Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants. Am J Transplant. 2021;21(11):3734-3742. doi:10.1111\/ajt.16747","DOI":"10.1111\/ajt.16747"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325(7):454-460. doi:10.1056\/NEJM199108153250702","DOI":"10.1056\/NEJM199108153250702"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. D'Ambrosio R, Vinci M, Franchina M, et al. Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. Kidney Int. 2019;95(4):993-995. doi:10.1016\/j.kint.2018.11.037","DOI":"10.1016\/j.kint.2018.11.037"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373(4):303-305. doi:10.1056\/NEJMp1505074","DOI":"10.1056\/NEJMp1505074"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4(12):2032-2037. doi:10.1046\/j.1600-6143.2004.00606.x","DOI":"10.1046\/j.1600-6143.2004.00606.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Zahid MN. Transplantation of organs from hepatitis c virus-positive donors under direct-acting antiviral regimens. J Clin Med. 2022;11(3):770. doi:10.3390\/jcm11030770","DOI":"10.3390\/jcm11030770"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Shetty A, Ariyamuthu VK, Gungor AB, Tanriover B. Utilization of hepatitis C virus-positive donors in kidney transplantation. Curr Opin Organ Transplant. 2023;28(1):22-28. doi:10.1097\/MOT.000000000000103","DOI":"10.1097\/MOT.0000000000001031"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting hepatitis C virus-infected versus uninfected kidneys into hepatitis C virus-infected recipients: a cost-effectiveness analysis. Ann Intern Med. 2018;169(4):214-223. doi:10.7326\/M17-3088","DOI":"10.7326\/M17-3088"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395. doi:10.1056\/NEJMc1705221","DOI":"10.1056\/NEJMc1705221"},{"key":"ref16","unstructured":"17. Goldberg D, Reese P, Potluri V, Scott F. Offering HCV-positive kidneys to HCV-negative patients on the kidney transplant waitlist is lifesaving: results of a Markov model. Am J Transplant. 2016;16(suppl 3). https:\/\/atcmeetingabstracts.com\/abstract\/offering-hcv-positive-kidneys-to-hcv-negative-patients-on-the-kidney-transplant-waitlist-is-lifesaving-results-of-a-markov-model\/"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Li LF, Shi KQ, Lin YQ, et al. Factors associated with efficacy of pegylated interferon-\u03b1 plus ribavirin for chronic hepatitis C after renal transplantation. Gene. 2014;544(2):101-106. doi:10.1016\/j.gene.2014.04.072","DOI":"10.1016\/j.gene.2014.04.072"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Sanai FM, Mousa D, Al-Mdani A, et al. Safety and efficacy of peginterferon-\u03b12a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol. 2013;58(6):1096-103. doi:10.1016\/j.jhep.2013.02.004","DOI":"10.1016\/j.jhep.2013.02.004"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Delabaudi\u00e8re C, Lavayssi\u00e8re L, D\u00f6rr G, et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int. 2015;28(2):255-258. doi:10.1111\/tri.12428","DOI":"10.1111\/tri.12428"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int. 2009;22(5):562-567. doi:10.1111\/j.1432-2277.2008.00831.x","DOI":"10.1111\/j.1432-2277.2008.00831.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Rawashdeh B, AlRyalat SA, Abuassi M, Prasad R, Cooper M. Unveiling transplantation research productivity of United States: a bibliometric analysis. World J Transplant. 2023;13(6):391-402. doi:10.5500\/wjt.v13.i6.391","DOI":"10.5500\/wjt.v13.i6.391"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Rawashdeh B, El-Hinnawi A, AlRyalat SA, Oberholzer J. Application of robotics in abdominal organ transplantation: a bibliometric analysis. Int J Med Robot. 2023;19(5):e2527. doi:10.1002\/rcs.2527","DOI":"10.1002\/rcs.2527"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Rawashdeh B, AlRyalat SA, Abuassi M, et al. Impact of COVID-19 on abdominal organ transplantation: a bibliometric analysis. Transpl Infect Dis. 2023;25(3):e14027. doi:10.1111\/tid.14027","DOI":"10.1111\/tid.14027"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Rawashdeh B. Insights and limitations of bibliometric analysis in solid organ transplantation. Prog Transplant. 2024;34(3):67-69. doi:10.1177\/15269248241275431","DOI":"10.1177\/15269248241275431"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. J Vis Exp. 2019;(152). doi:10.3791\/58494","DOI":"10.3791\/58494"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338-342. doi:10.1096\/fj.07-9492LSF","DOI":"10.1096\/fj.07-9492LSF"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:13:12Z","timestamp":1785838392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2026\/24\/7\/0\/513\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2026.0045","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}